Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Trading Up 16.4% – Here’s What Happened

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price was up 16.4% on Thursday . The stock traded as high as $13.37 and last traded at $13.10. 1,369,571 shares were traded during trading, an increase of 4% from the average daily volume of 1,317,666 shares. The stock had previously closed at $11.25.

More Bayer Aktiengesellschaft News

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: The U.S. Supreme Court sided with Bayer in the Roundup warning-label case, a decision that may significantly reduce future lawsuit risk and improve the company’s ability to resolve outstanding claims. Bayer wins Supreme Court case making it harder to sue over glyphosate in Monsanto’s Roundup
• Positive Sentiment: Investors are reacting to the possibility that Bayer’s decades-long Roundup legal overhang could become easier to manage, which supports a rerating of the stock. Bayer Gets New Life After Supreme Court’s Roundup Ruling
• Positive Sentiment: Analysts note that Bayer’s shares have surged on unusually heavy volume following the ruling, reflecting strong investor enthusiasm around the legal victory. Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The stock has a 50 day moving average of $10.97 and a 200 day moving average of $11.50. The company has a market capitalization of $52.27 billion, a price-to-earnings ratio of -20.78, a price-to-earnings-growth ratio of 4.23 and a beta of 0.59. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.